Goldman Sachs analyst Paul Choi upgraded The Medicines Co. to Buy from Neutral and raised his price target for the shares to $55 from $25. The target implies 90% upside from the current price of $29.80. The analyst says that with the Orion Phase 3 topline results expected in Q3, his comfort level with inclisiran's benefit/risk profile has increased based on the recent updates from the independent data monitoring committee and a separate update for givosiran, which uses the same ESC-GalNAc conjugate platform. Further, new management is taking the appropriate steps to right-size the cost base and capital structure, Choi tells investors in a research note. This sets up inclisiran for a successful launch, which should also increase The Medicines Co.'s potential appeal to partner or strategic buyer, adds the analyst. Choi also thinks near term consensus launch expectations are achievable.